(Q37863629)

24 August 2017

1 reference

title

Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors (English)

1 reference

24 August 2017

1 reference

David Berz

1

1 reference

24 August 2017

Harold Wanebo

series ordinal

2

1 reference

24 August 2017

publication date

1 May 2011

1 reference

Journal of Surgical Oncology

24 August 2017

published in

1 reference

24 August 2017

volume

103

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

574-586

1 reference

Overview of targeted therapies in oncology

24 August 2017

cites work

1 reference

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Gastrointestinal stromal tumors: a paradigm for therapeutic options in solid organ tumors

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

HER family inhibitors in pancreatic cancer: current status and future directions

21 January 2018

1 reference

21 January 2018

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.

21 January 2018

1 reference

The epidermal growth factor receptor in human pancreatic cancer

21 January 2018

1 reference

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

A decade of tyrosine kinases: from gene discovery to therapeutics

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes

21 January 2018

1 reference

Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants

21 January 2018

1 reference

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer

21 January 2018

1 reference

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

21 January 2018

1 reference

Overview of tyrosine kinase inhibitors in clinical breast cancer.

21 January 2018

1 reference

Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

21 January 2018

1 reference

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

HER2 as a target for breast cancer therapy.

21 January 2018

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

21 January 2018

1 reference

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

21 January 2018

1 reference

K-ras mutations in non-small-cell lung carcinoma: a review

21 January 2018

1 reference

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

21 January 2018

1 reference

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

21 January 2018

1 reference

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

21 January 2018

1 reference

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

21 January 2018

1 reference

Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study

21 January 2018

1 reference

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

21 January 2018

1 reference

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

Emerging targeted therapies for breast cancer

21 January 2018

1 reference

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

21 January 2018

1 reference

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

21 January 2018

1 reference

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

21 January 2018

1 reference

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

21 January 2018

1 reference

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer

21 January 2018

1 reference

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer

21 January 2018

1 reference

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

Molecular testing in lung cancer: the time is now.

21 January 2018

1 reference

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

21 January 2018

1 reference

Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.

21 January 2018

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

21 January 2018

1 reference

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

21 January 2018

1 reference

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

21 January 2018

1 reference

Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis

21 January 2018

1 reference

Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma

21 January 2018

1 reference

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.

21 January 2018

1 reference

Rationale for new drugs targeting the tissue microenvironment in patients with HCC.

21 January 2018

1 reference

Molecular pathways and related target therapies in liver carcinoma.

21 January 2018

1 reference

Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway

21 January 2018

1 reference

Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells

21 January 2018

1 reference

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

Tyrosine kinase inhibitors to treat liver cancer

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.

21 January 2018

1 reference

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials

21 January 2018

1 reference

Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.

21 January 2018

1 reference

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms

21 January 2018

1 reference

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

21 January 2018

1 reference

New paradigms in gastrointestinal stromal tumour management.

21 January 2018

1 reference

Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma

21 January 2018

1 reference

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.21776

1 reference

24 August 2017

1 reference